Zevra Therapeutics (ZVRA) Debt to Equity (2020 - 2025)
Zevra Therapeutics' Debt to Equity history spans 8 years, with the latest figure at $0.4 for Q4 2025.
- For Q4 2025, Debt to Equity fell 73.31% year-over-year to $0.4; the TTM value through Dec 2025 reached $0.4, down 73.31%, while the annual FY2025 figure was $0.4, 73.31% down from the prior year.
- Debt to Equity reached $0.4 in Q4 2025 per ZVRA's latest filing, down from $0.46 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $1.8 in Q2 2024 to a low of $0.01 in Q1 2021.
- Average Debt to Equity over 5 years is $0.68, with a median of $0.52 recorded in 2025.
- Peak YoY movement for Debt to Equity: skyrocketed 923.86% in 2024, then crashed 73.31% in 2025.
- A 5-year view of Debt to Equity shows it stood at $0.01 in 2021, then soared by 1291.48% to $0.13 in 2022, then surged by 435.93% to $0.69 in 2023, then soared by 117.0% to $1.5 in 2024, then tumbled by 73.31% to $0.4 in 2025.
- Per Business Quant, the three most recent readings for ZVRA's Debt to Equity are $0.4 (Q4 2025), $0.46 (Q3 2025), and $0.52 (Q2 2025).